RO 314724

Drug Profile

RO 314724

Latest Information Update: 09 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Matrix metalloproteinase 3 inhibitors; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 09 Nov 2006 Discontinued for Osteoarthritis (unspecified route)
  • 09 Nov 2006 Discontinued for Rheumatoid arthritis (unspecified route)
  • 19 Nov 2001 No-Development-Reported for Osteoarthritis (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top